Efficient induction of apoptosis by Wee1 kinase inhibition in hepatocellular carcinoma cells

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Kogiso, Tomomi ^a   Nagahara, Hikaru ^a   Hashimoto, Etsuko ^a   Ariizumi, Shunichi ^a   Yamamoto, Masakazu ^a   Shiratori, Keiko ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ENZYME; CYCLIN DEPENDENT KINASE 1; ENZYME INHIBITOR; PD 166285; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; WEE1 KINASE; WEE1 KINASE INHIBITOR; CDK1 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; WEE1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYME ACTIVATION; GENE EXPRESSION; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; METABOLISM; RNA INTERFERENCE; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; ENZYME ACTIVATION; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84903524091     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100495     Document Type: Article

References (30)

1. Block TM, Mehta AS, Fimmel CJ, Jordan R (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene 22: 5093-5107. (Pubitemid 37059591)
2. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466. (Pubitemid 39329586)
3. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442. (Pubitemid 36152543)
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
5. Bruix J, Sherman M, Practice Guidelines Committee AeAftSoLD (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236. (Pubitemid 43112690)
6. Gauthier A, Ho M (2012) Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res.
7. Liu L, Cao Y, Chen C, Zhang X, McNabola A, et al. (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858. (Pubitemid 46094197)
8. Massagué J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309.
9. Massagué J (2004) G1 cell-cycle control and cancer. Nature 432: 298-306.
10. Nagahara H, Ezhevsky SA, Vocero-Akbani AM, Kaldis P, Solomon MJ, et al. (1999) Transforming growth factor beta targeted inactivation of cyclin E:cyclindependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity. Proc Natl Acad Sci U S A 96: 14961-14966. (Pubitemid 30019747)
11. Choi KS, Eom YW, Kang Y, Ha MJ, Rhee H, et al. (1999) Cdc2 and Cdk2 kinase activated by transforming growth factor-beta1 trigger apoptosis through the phosphorylation of retinoblastoma protein in FaO hepatoma cells. J Biol Chem 274: 31775-31783.
12. Krek W, Nigg EA (1991) Differential phosphorylation of vertebrate p34cdc2 kinase at the G1/S and G2/M transitions of the cell cycle: identification of major phosphorylation sites. EMBO J 10: 305-316. (Pubitemid 21905480)
13. Krek W, Nigg EA (1991) Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates. EMBO J 10: 3331-3341. (Pubitemid 21905358)
14. Krek W, Nigg EA (1992) Cell cycle regulation of vertebrate p34cdc2 activity: identification of Thr161 as an essential in vivo phosphorylation site. New Biol 4: 323-329.
15. Norbury C, Blow J, Nurse P (1991) Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. EMBO J 10: 3321-3329. (Pubitemid 21905357)
16. Solomon MJ, Lee T, Kirschner MW (1992) Role of phosphorylation in p34cdc2 activation: identification of an activating kinase. Mol Biol Cell 3: 13-27. (Pubitemid 23094249)
17. Wang Y, Li J, Booher RN, Kraker A, Lawrence T, et al. (2001) Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res 61: 8211-8217. (Pubitemid 33091614)
18. Li J, Wang Y, Sun Y, Lawrence TS (2002) Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Radiat Res 157: 322-330. (Pubitemid 34263846)
19. Jang CW, Chen CH, Chen CC, Chen JY, Su YH, et al. (2002) TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat Cell Biol 4: 51-58. (Pubitemid 34071980)
20. Claassen GF, Hann SR (2000) A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. Proc Natl Acad Sci U S A 97: 9498-9503. (Pubitemid 30650804)
21. Perlman R, Schiemann WP, Brooks MW, Lodish HF, Weinberg RA (2001) TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol 3: 708-714. (Pubitemid 32734248)
22. Yilmaz M, Maass D, Tiwari N, Waldmeier L, Schmidt P, et al. (2011) Transcription factor Dlx2 protects from TGFβ-induced cell-cycle arrest and apoptosis. EMBO J 30: 4489-4499.
23. O'Connor DS, Wall NR, Porter AC, Altieri DC (2002) A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2: 43-54.
24. Chang CC, Heller JD, Kuo J, Huang RC (2004) Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A 101: 13239-13244. (Pubitemid 39209649)
25. Harris PS, Venkataraman S, Alimova I, Birks DK, Balakrishnan I, et al. (2014) Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol Cancer 13: 72.
26. Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, et al. (2012) Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia 26: 1266-76.
27. Janssen A, Medema RH (2011) Mitosis as an anti-cancer target. Oncogene 30: 2799-809.
28. Russell P, Nurse P (1987) Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog. Cell 49: 559-67.
29. De Witt Hamer PC, Mir SE, Noske D, Van Noorden CJ, Würdinger T (2011) WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res 17: 4200-4207.
30. Leijen S, Beijnen JH, Schellens JH (2010) Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol 5: 186-191.